Search
Remifentanil
go.drugbank.com/drugs/DB00899ApprovedInvestigationalRemifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia. … Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic.
Categories: Heterocyclic Compounds, 1-RingProducts: ULTIVA 1 MG ENJEKTABL TOZ İÇEREN FLAKON, 5 ADET, REMIFENTANIL B. BRAUNDidanosine
go.drugbank.com/drugs/DB00900ApprovedInvestigationalA dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. … Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative
Categories: Heterocyclic Compounds, 2-RingSynonyms: 2',3'-dideoxyinosine, 9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-oneOndansetron
go.drugbank.com/drugs/DB00904ApprovedInvestigationalWithdrawnA competitive serotonin type 3 receptor antagonist. … [L5221] The FDA withdrew its approval for the use of all intravenous drug products containing more than 16 mg of ondansetron hydrochloride in a single dose, due to a high risk of QT prolongation.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: BRYTEROL® TABLETAS X 8 MG, ZOPHRALEN 4 MG/2 ML IV AMPUL, 5 ADETQuinidine
go.drugbank.com/drugs/DB00908ApprovedQuinidine is a D-isomer of [quinine] present in the bark of the Cinchona tree and similar plant species. … This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexSynonyms: (R)-(6-Methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol, (S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanolZonisamide
go.drugbank.com/drugs/DB00909ApprovedInvestigational[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors … Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: Benzo[d]isoxazol-3-yl-methanesulfonamide, 1,2-Benzisoxazole-3-methanesulfonamideTinidazole
go.drugbank.com/drugs/DB00911ApprovedInvestigationalA nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections.
Mixtures: GYNOMAX L VAJINAL OVUL, 7 ADET, GYNOMAX 100 MG/150 MG VAJINAL OVUL, 7 ADETCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingRepaglinide
go.drugbank.com/drugs/DB00912ApprovedInvestigationalApproximately 90% of a single orally administered dose is eliminated in feces and 8% in urine. … Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight.
Mixtures: REPAMEF 1/1000 MG EFERVESAN TABLET, 30 ADET, REPAMEF 1/500 MG EFERVESAN TABLET, 30 ADETCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingBuprenorphine
go.drugbank.com/drugs/DB00921ApprovedIllicitInvestigationalVet approved[L46571] Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with [naloxone], a non-selective competitive opioid … Clinically, this results in a slow onset of action and a clinical phenomenon known as the "ceiling effect" where once a certain dose is reached, buprenorphine's effects plateau.
Mixtures: SUBOXONE 8 MG/2 MG DILALTI TABLET, 7 ADET, Suboxone 8 mg/2 mg sublingual tabletsCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesCyclobenzaprine
go.drugbank.com/drugs/DB00924ApprovedInvestigationalCyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been available for human use since 1977. … [A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.
Mixtures: DOBRIX ®, Therabenzaprine-90-5Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPhenoxybenzamine
go.drugbank.com/drugs/DB00925ApprovedInvestigationalIt has been used to treat hypertension and as a peripheral vasodilator.
Categories: Peripheral alpha-1 blockers, Adrenergic alpha-1 Receptor Antagonists